-
Je něco špatně v tomto záznamu ?
Diabetes a revaskularizační techniky: dobré zprávy!
[Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial]
J. Daemen, et al.
Jazyk čeština Země Česko
- MeSH
- balónková koronární angioplastika MeSH
- časové faktory MeSH
- cévní mozková příhoda epidemiologie etiologie MeSH
- diabetes mellitus patofyziologie MeSH
- financování organizované MeSH
- imunosupresiva terapeutické užití MeSH
- incidence MeSH
- infarkt myokardu epidemiologie etiologie MeSH
- interval spolehlivosti MeSH
- komplikace diabetu terapie MeSH
- koronární bypass MeSH
- lidé středního věku MeSH
- lidé MeSH
- náhlá srdeční smrt epidemiologie etiologie MeSH
- následné studie MeSH
- nemoci koronárních tepen farmakoterapie chirurgie terapie MeSH
- odds ratio MeSH
- prospektivní studie MeSH
- revaskularizace myokardu metody MeSH
- rizikové faktory MeSH
- sirolimus terapeutické užití MeSH
- stenty uvolňující léky MeSH
- studie případů a kontrol MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
The purpose of this study was to assess the 3-year outcome of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SES) in patients who had multivessel coronary artery disease with and without diabetes mellitus. BACKGROUND: The optimal method of revascularization in diabetic patients remains in dispute. METHODS: The ARTS-II (Arterial Revascularization Therapies Study-Part II) trial is a single-arm study (n = 607) that included 159 diabetic patients treated with SES whose 3-year clinical outcome was compared with that of the historical diabetic and nondiabetic arms of the randomized ARTS-I trial (n = 1,205, including 96 diabetic patients in the CABG arm and 112 in the PCI arm). RESULTS: At 3 years, among nondiabetic patients, the incidence of the primary composite of death, CVA, myocardial infarction (MI), and repeat revascularization (major adverse cardiac and cerebrovascular events [MACCE]), was significantly lower in ARTS-II than in ARTS-I PCI (adjusted odds ratio [OR]: 0.41; 95% confidence interval [CI]: 0.26 to 0.64) and similar to ARTS-I CABG. The ARTS-II patients were at significantly lower risk for death, CVA, and MI as compared with both the ARTS-I PCI (adjusted OR: 0.55; 95% CI: 0.34 to 0.91) and ARTS-I CABG patients (adjusted OR: 0.56; 95% CI: 0.35 to 0.92). Among diabetic patients, the incidence of MACCE in ARTS-II was similar to that of both PCI and CABG in ARTS-I. Conversely, the incidence of death, CVA, and MI was significantly lower in ARTS-II than in ARTS-I PCI (adjusted OR: 0.67; 95% CI: 0.27 to 1.65) and was similar to that of ARTS-I CABG. CONCLUSIONS: At 3 years, PCI using SES for patients with multivessel coronary artery disease seems to be safer and more efficacious than PCI using bare-metal stents, irrespective of the diabetic status of the patient. Hence, PCI using SES appears to be a valuable alternative to CABG for both diabetic and nondiabetic patients.
Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07527974
- 003
- CZ-PrNML
- 005
- 20111210144148.0
- 008
- 090831s2009 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Daemen, J.
- 245 10
- $a Diabetes a revaskularizační techniky: dobré zprávy! / $c J. Daemen, et al.
- 246 11
- $a Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial
- 314 __
- $a Thoraxcenter, Erasmus Medical Center, Rotterdam
- 520 9_
- $a The purpose of this study was to assess the 3-year outcome of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SES) in patients who had multivessel coronary artery disease with and without diabetes mellitus. BACKGROUND: The optimal method of revascularization in diabetic patients remains in dispute. METHODS: The ARTS-II (Arterial Revascularization Therapies Study-Part II) trial is a single-arm study (n = 607) that included 159 diabetic patients treated with SES whose 3-year clinical outcome was compared with that of the historical diabetic and nondiabetic arms of the randomized ARTS-I trial (n = 1,205, including 96 diabetic patients in the CABG arm and 112 in the PCI arm). RESULTS: At 3 years, among nondiabetic patients, the incidence of the primary composite of death, CVA, myocardial infarction (MI), and repeat revascularization (major adverse cardiac and cerebrovascular events [MACCE]), was significantly lower in ARTS-II than in ARTS-I PCI (adjusted odds ratio [OR]: 0.41; 95% confidence interval [CI]: 0.26 to 0.64) and similar to ARTS-I CABG. The ARTS-II patients were at significantly lower risk for death, CVA, and MI as compared with both the ARTS-I PCI (adjusted OR: 0.55; 95% CI: 0.34 to 0.91) and ARTS-I CABG patients (adjusted OR: 0.56; 95% CI: 0.35 to 0.92). Among diabetic patients, the incidence of MACCE in ARTS-II was similar to that of both PCI and CABG in ARTS-I. Conversely, the incidence of death, CVA, and MI was significantly lower in ARTS-II than in ARTS-I PCI (adjusted OR: 0.67; 95% CI: 0.27 to 1.65) and was similar to that of ARTS-I CABG. CONCLUSIONS: At 3 years, PCI using SES for patients with multivessel coronary artery disease seems to be safer and more efficacious than PCI using bare-metal stents, irrespective of the diabetic status of the patient. Hence, PCI using SES appears to be a valuable alternative to CABG for both diabetic and nondiabetic patients.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a balónková koronární angioplastika $7 D015906
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a interval spolehlivosti $7 D016001
- 650 _2
- $a koronární bypass $7 D001026
- 650 _2
- $a nemoci koronárních tepen $x farmakoterapie $x chirurgie $x terapie $7 D003324
- 650 _2
- $a náhlá srdeční smrt $x epidemiologie $x etiologie $7 D016757
- 650 _2
- $a komplikace diabetu $x terapie $7 D048909
- 650 _2
- $a diabetes mellitus $x patofyziologie $7 D003920
- 650 _2
- $a stenty uvolňující léky $7 D054855
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infarkt myokardu $x epidemiologie $x etiologie $7 D009203
- 650 _2
- $a revaskularizace myokardu $x metody $7 D009204
- 650 _2
- $a odds ratio $7 D016017
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a sirolimus $x terapeutické užití $7 D020123
- 650 _2
- $a cévní mozková příhoda $x epidemiologie $x etiologie $7 D020521
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 773 0_
- $w MED00012706 $t Clinical cardiology alert $g Roč. 3, č. 2 (2009), s. 15 $x 1213-2586
- 787 18
- $w bmc07527975 $i Recenze v: $t Komentář [k článku Diabetes a revaskularizační techniky: dobré zprávy!]
- 910 __
- $a ABA008 $b B 2242 $c 407 a $y 8
- 990 __
- $a 20090828103115 $b ABA008
- 991 __
- $a 20100202133322 $b ABA008
- 999 __
- $a ok $b bmc $g 673506 $s 532771
- BAS __
- $a 3
- BMC __
- $a 2009 $b 3 $c 2 $d 15 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
- LZP __
- $a 2009-30/mkme
